CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-14). The draft was written by AI, the existence of all 1 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.7.
Verdict No. 2561 · Search date 2026-08-14 · Methodology v0.7

HFNC immediately after planned extubation,
does it really help with Reduced reintubation within 72 hours versus conventional oxygen?

30-Second Summary
B
Evidence Grade B · 72 · Safety caution
HFNC immediately after planned extubation reduced 72-hour reintubation in low-risk adults.
The trial reported zero nasal or skin trauma; dryness and abdominal distension were not measured or reported. ICU monitoring remains necessary so deterioration is recognized and reintubation is not delayed.
What the
research shows
The grade is B. A seven-ICU Spanish trial analyzed all 527 participants. Reintubation within 72 hours occurred in 13/264 (4.9%) with HFNC versus 32/263 (12.2%) with conventional oxygen, an absolute difference of 7.2 percentage points (95% CI 2.5 to 12.2). The clinical event fell significantly, but there is no independent replication of the same low-risk, conventional-oxygen comparison; the analyst was masked, whereas treating staff and reintubation decision-makers were not, giving B with 72 points.
What the
ads claim
HFNC delivers warmed, humidified gas at high flow through nasal cannulae. Evidence applies to 24 hours immediately after planned extubation in low-risk adults, not indiscriminately to high-risk patients, unplanned extubation, or home use.
*

Useful facts when choosing a product

  • HFNC delivers warmed and humidified gas at high flow through nasal cannulae.
  • Verdict 2561 concerns low-risk patients, HFNC versus conventional oxygen, and 72 hours. Verdict 2543 is B with 72 points and concerns high-risk patients, NIV versus HFNC, and seven days.
  • Fisher & Paykel supplied blenders to two of seven ICUs and was reported to have no other study role.
Gap Measurement · Verdict 2561 · B 72
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Hernández G, Vaquero C, González P and colleagues randomized 527 participants, 264 versus 263, and analyzed all of them. The paper described concealed allocation through a telephone call center and intention-to-treat analysis. The analyst was masked, whereas treating staff and reintubation decision-makers were not. The study reported no external funding; Fisher & Paykel supplied air-oxygen blenders to two ICUs with no other study role. The paper's 72-hour primary endpoint matched NCT01191489.

02

Why this is classified as B (72)

An all-participant multicenter trial reduced actual reintubation, but the exact low-risk conventional-oxygen comparison lacks independent replication; the analyst was masked, whereas treating staff and reintubation decision-makers were not, giving B with 72 points.

Counterpoint. B does not mean every extubated patient requires HFNC; the verdict is limited to 72-hour reintubation in low-risk adults.

Rejudgment record. Cross-check applied — We cross-checked allocation concealment, all 527 randomized participants, the registered 72-hour primary endpoint, event counts, masking, and device provision against the article and registry.

Scoring profile behind this grade
EndpointHHard endpoint - actual events such as death
ReplicationR1Single confirmatory trial
IndependenceI1Mixed funding sources
Effect sizeE+Meets the clinically important threshold

The scoring table and the verdict agree (B).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Reduced 72-hour reintubation in low-risk adultsBRates were 4.9% versus 12.2%, with the full interval favoring HFNC.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Multicenter randomized trial in seven Spanish ICUs0No external funding; Fisher & Paykel supplied blenders to two ICUsReintubation within 72 hours after extubation13/264 (4.9%) versus 32/263 (12.2%), absolute difference 7.2 points (95% CI 2.5 to 12.2), P=.004Only direct confirmatory hard-outcome trial
§

Receipt — 1 References

All 1 cited sources were verified for existence at the original page (as of 2026-08-14).

Hernández G, Vaquero C, González P, et al. Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients: A Randomized Clinical Trial. JAMA. 2016;315(13):1354-1361. PMID: 26975498. DOI: 10.1001/jama.2016.2711. NCT01191489.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-14 · Corrections: none

Cite this verdict

HFNC immediately after planned extubation x 72-hour reintubation Evidence Grade B card
[Chamgap] HFNC immediately after planned extubation x 72-hour reintubation — Evidence Grade B·72. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/general/hfno-low-risk-planned-extubation-reintubation/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.